|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||72.51 - 74.38|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.45|
|Earnings Date||Feb 5, 2018 - Feb 9, 2018|
|Forward Dividend & Yield||2.08 (2.86%)|
|1y Target Est||85.70|
Kite, a Gilead Company , announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ in patients with refractory large B-cell lymphoma.
Shares of Gilead Sciences (GILD) are higher Friday, after it announced its acquisition of Cell Design Labs. Kite Pharma, which Gilead bought earlier this year, already owned some 12% of the firm, so Gilead ...
Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Gilead Sciences Inc. said late Thursday it will acquire privately held cellular therapy company Cell Design Labs Inc. for $567 million. The company said it will acquire the 12.2% of Cell Design shares ...
Gilead Sciences, Inc. and its cell therapy subsidiary Kite announced today that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy.
–Demonstrates Gilead’ s Deep Commitment to Cell Therapy–. –Novel Cell Engineering Technologies with the Potential to Drive Discovery and Development of New Anti-Cancer Medicines–. –Structured Buy Out to ...
Gilead has a potential GOAT on its hands, an analyst said Wednesday. Its drug, bictegravir, is likely to become the "Greatest Of All Time" among HIV drug launches.
Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...
Gilead Sciences, Inc. today announced the launch of the Gilead COMPASS Initiative, a 10-year, $100 million commitment to support organizations working to address the HIV/AIDS epidemic in the Southern United States.
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
This article first appeared on SumZero, the world’s largest research community of buyside investment professionals. Gilead Sciences is a pharmaceutical company with two main revenue streams — Hepatitis C and HIV medications. The former is in a state of decline, as Gilead (GILD) has been able to bring a cure to market.
NEW YORK, Nov. 28, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Garmin ...
Gilead (GILD) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.